News

Article

CordenPharma Announces New Capacity Expansions at its US and Germany Sites

The expansions will add peptide manufacturing capacity.

CordenPharma announced on May 13, 2021 that it plans to expand its non-GMP capacity at its Centre of Excellence for Peptide Process Development in Frankfurt, Germany, and increase its upstream capacity at its CordenPharma Colorado site with the introduction of a new 3000-L solid phase peptide synthesis (SPPS) vessel.

The capacity expansions fall in line with CordenPharma’s strategy to provide its customers with quick and economically appealing solutions, the company said in a press release. In addition to the new SPPS vessel, CordenPharma plans to add a second 100-cm high-pressure chromatography column at its CordenPharma Colorado site.

“This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80-cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners,” said Matthieu Giraud, PhD, global director of the Peptides, Lipids & Carbohydrates Platform, CordenPharma, in the press release.

Source: CordenPharma

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content